CRIANN boosts bandwidth in French research and education network with Adtran FSP 3000
Adtran today announced that the Centre Régional Informatique et d’Applications Numériques de Normandie (CRIANN) is using its FSP 3000 optical transport technology and ALM fiber monitoring platform to boost the capacity and resilience of its research and education network, thanks to the financial support of the Normandy Region. By integrating Adtran’s solution, the Normandy-based supercomputing center and provider of high-performance digital infrastructure is ensuring faster and more reliable connectivity for the region’s scientific and academic institutions. Adtran’s Elite partner Axians also played a key role in the installation and continues to deliver maintenance and support.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104047734/en/
Adtran’s technology is helping CRIANN drive high-speed, secure and ultra-reliable connectivity throughout its research and education network. (Photo: Business Wire)
“Our fiber network promotes innovation and the advancement of scientific knowledge. We support academic institutions in several ways, including by enabling data-intensive simulations and AI research for which high-speed, secure and ultra-reliable connectivity is fundamental,” said Alain Bidaud, CTO of CRIANN. “Harnessing Adtran’s optical transport technology, we’ve boosted capacity across our fiber infrastructure while also rendering our services more resilient. The FSP 3000 enables a seamless transition from our existing transport network. What’s more, its modular architecture radically simplifies the upgrade process so we can augment the solution to efficiently and sustainably meet future demand.”
This major upgrade to CRIANN’s research and education network increases bandwidth across all three of its sites. Featuring Adtran’s FSP 3000 OpenFabric™ 1200, the new solution integrates an open and flexible OTN fabric with DWDM transponder functions that deliver up to 400Gbit/s per wavelength and supports multiple OTN and Ethernet client services from 10Gbit/s to 400Gbit/s on a single card. This enables CRIANN to boost transport capacity and ensures the network can easily scale to meet both current and future demands.
CRIANN has also deployed Adtran’s ALM in-service fiber monitoring platform, which provides rapid, detailed alerts in the event of any fiber disruption. Combined with Adtran’s Mosaic Network Controller and Fiber Director, it offers a sophisticated real-time geographic information system that delivers pinpoint accuracy in locating fiber issues. By empowering CRIANN’s maintenance team with a precise understanding of its fiber infrastructure, the technology helps reduce truck rolls, improves network availability and minimizes operating costs.
“Built on our FSP 3000 platform, CRIANN’s upgraded fiber infrastructure is ideally suited to meet the growing demands of research and education networks for higher capacity and greater reliability,” commented Stuart Broome, GM of EMEA sales at Adtran. “Harnessing our OpenFabric™ 1200 switchponder, the new solution supports Ethernet and OTN services up to 400Gbit/s. This technology simplifies operations and maximizes the potential of CRIANN’s fiber assets. With its new, robust network, CRIANN is empowering Normandy’s academic community to take their research to whole new levels.”
“At Axians, we believe in forging connections that matter, not just with technology but also through relationships. Our partnership with CRIANN and Adtran is a testament to this philosophy. Together, we’re ensuring CRIANN’s research and education network can adapt, evolve and meet future challenges,” noted Bruno Durand, GM of Axians communication and cloud Caen. “This deployment is about providing top-tier opportunities for scientists, teachers and students. By merging technical expertise with our commitment to delivering excellence, we’re ensuring that the region stays at the cutting edge of research and innovation.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104047734/en/
Contacts
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Rhonda Lambert
+1 256 963 7450
investor.relations@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom